MONOCLONAL ANTIBODY MSL 109 CMV RETINITIS TRIAL

单克隆抗体 MSL 109 CMV 视网膜炎试验

• 批准号: 6275245
• 负责人: MURK-HEIN HEINEMANN
• 金额: $ 5.51万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6275245
• 关键词: AIDS therapy; antiviral antibody; clinical research; clinical trials; cytomegalovirus; eye disorder chemotherapy; human subject; human therapy evaluation; immunopharmacology; monoclonal antibody; placebos; relapse /recurrence; retinitis

The primary objective of the Monoclonal Antibody CMV Retinitis Trial is to compare the safety and efficacy of Human Anti-CMV Monoclonal Antibody versus matched placebo plus active primary treatment, for both newly diagnosed and relapsed CMV retinitis in patients with AIDS.

单克隆抗体CMV视网膜炎试验的主要目的是 比较人源抗CMV单克隆抗体的安全性和有效性 与匹配的安慰剂+活性药物主要治疗相比， 诊断和复发的CMV视网膜炎的艾滋病患者。